




PHARMACEUTICAL 2019

ChemoCentryx Inc.
Rank 263 of 363





PHARMACEUTICAL 2019

ChemoCentryx Inc.
Rank 263 of 363



The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 40% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.2%, being 44% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	181,384
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	64,396
Liabilities, Non-Current	20,076
Other Assets	390
Other Compr. Net Income	-79
Other Expenses	0
Other Liabilities	84,100
Other Net Income	2,304
Other Revenues	42,875
Property and Equipment	1,536
Research and Development	62,736
Selling, General and Administrative Expense	20,409

Output Variable	Value in 1000 USD
Assets	183,310
Liabilities	168,572
Expenses	83,145
Revenues	42,875
Stockholders Equity	14,738
Net Income	-37,966
Comprehensive Net Income	-38,006
Economic Capital Ratio	-7.2%